Jeff Jensen MD/PhD
LightNews LightNews
banner
drjensen.bsky.social
Jeff Jensen MD/PhD
@drjensen.bsky.social
7 followers 13 following 9 posts
I am a lung cancer medical oncologist researching NUT carcinoma and PRAME
Posts Replies Media Videos
Reposted by Jeff Jensen MD/PhD
sitcancer.bsky.social
Congratulations Dr. Jensen!
February 5, 2026 at 3:49 PM
drjensen.bsky.social
Our latest research showing PRAME as a previously unrecognized therapeutic target in NUT carcinoma just dropped on JITC. Huge thanks to @sitcancer.bsky.social @benjamingvincent.bsky.social @alexr.bsky.social @unclineberger.bsky.social and so may others!!!

jitc.bmj.com/content/14/2...
Shared PRAME epitopes are T-cell targets in NUT carcinoma
Background NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NU...
jitc.bmj.com
February 5, 2026 at 1:54 PM
drjensen.bsky.social
@lizbwood.bsky.social I am an early career physician scientist @unclineberger.bsky.social we are trying to open PRAME immunotherapy trials and saw your work @sitcancer.bsky.social can we discuss???

@benjamingvincent.bsky.social @alexr.bsky.social
February 3, 2026 at 6:51 PM
drjensen.bsky.social
Congratulations to Zachary Hartman and colleagues @dukecancer.bsky.social on their latest paper on CD27 agonists as adjuvants for vaccines. Very cool!

doi.org/10.1126/scii...
CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
CD27 agonism enhances vaccine-induced CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.
doi.org
December 31, 2025 at 2:09 AM
drjensen.bsky.social
I thought the breakthrough of the year was PRAME in NUT carcinoma but looks like renewables won instead www.science.org/content/arti...
Science’s 2025 Breakthrough of the Year: The unstoppable rise of renewable energy
Clean energy infrastructure is being deployed with unmatched scale and speed—and China is leading the way
www.science.org
December 19, 2025 at 1:13 AM
drjensen.bsky.social
Passed my American Board of Internal Medicine Medical Oncology boards. Woooooo
December 9, 2025 at 3:02 PM
drjensen.bsky.social
www.fda.gov/drugs/resour...
Great drug but dysgeusia a major draw back
FDA grants traditional approval to tarlatamab-dlle for extensive stage
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage s
www.fda.gov
December 8, 2025 at 6:40 PM
drjensen.bsky.social
Another reason to love trilaciclib: less clonal hematopoiesis. Congratulations to Kelly Bolton Lab for a great study.

doi.org/10.1182/bloo...
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
AbstractTherapy-related myeloid neoplasms (tMN) are a fatal consequence of exposure to oncologic therapy. Prior work has demonstrated that the expansion of
doi.org
December 7, 2025 at 9:09 PM
Reposted by Jeff Jensen MD/PhD
jiajennyliu.bsky.social
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.

This technology will expand access to solid tumor cell therapy 🌟
November 7, 2025 at 7:29 PM